Axsome Therapeutics, Inc. (AXSM): R&D Expense
$183.28M
Year ended 2025-12-31
$187.86M
Trailing 12 months to 2026-06-30
+46.8%
3-year compound annual growth
+21.1%
5-year compound annual growth
+39.1%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $183.28M | -2.0% | 2026-02-23, From 2025-01-01 |
| 2024-12-31 | $187.08M | +91.0% | 2026-02-23, From 2024-01-01 |
| 2023-12-31 | $97.94M | +69.0% | 2026-02-23, From 2023-01-01 |
| 2022-12-31 | $57.95M | -0.2% | 2025-02-18, From 2022-01-01 |
| 2021-12-31 | $58.06M | -17.3% | 2024-02-23, From 2021-01-01 |
| 2020-12-31 | $70.24M | +30.9% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $53.65M | +128.3% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $23.50M | +17.7% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $19.96M | -5.9% | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | $21.20M | +212.8% | 2019-03-15, From 2016-01-01 |
| 2015-12-31 | $6.78M | +58.4% | 2018-03-07, From 2015-01-01 |
| 2014-12-31 | $4.28M | n/a | 2017-03-07, From 2014-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $183.28M | -2.0% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $160.22M | +69.9% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $124.03M | +17.9% |
| Insmed Inc (INSM) | 2025-12-31 | $771.09M | +28.9% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $750.00M | +7.4% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $96.85M | -13.2% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $106.23M | -2.4% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $85.84M | +16.1% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $44.54M | -11.4% |
Compare AXSM, TGTX, OPK, INSM side by side · Screen every company in Pharmaceutical Preparations ↗